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ABSTRACT  The development  of resistance  in response  to  interferon  depends
on cellular RNA synthesis  and probably  also on cellular  protein synthesis. The
evidence  for  these requirements  is  reviewed,  as well  as  the proposal  that this
evidence indicates the existence  of a specific  response  of the cell to interferon,  in-
volving  the  induced  synthesis  of an antiviral  protein.  Direct evidence for  such
an interpretation  has  not been  obtained,  and  alternative  explanations  are dis-
cussed which do not require quantitative  or qualitative  differences in the RNA
and protein  made in cells exposed  to interferon.  The possible  role  of the ribo-
some in the antiviral  action  of interferon  is also discussed.
When  Dr. Merigan  asked  for  a  discussion  of  an  aspect  of interferon  action
that was  controversial,  the  selection  of such a  topic  seemed  to present  little
difficulty.  However,  the topics  I will  talk about are two  which appear  to be
in danger of becoming  noncontroversial.  The first relates to the development
of resistance and the significance  of the requirement this has for cellular RNA
and protein synthesis. The second topic I will talk about concerns the possible
role of the ribosome in the antiviral action of interferon.
With respect to the development  of resistance,  the question I would like to
consider is whether interferon  action involves a specific  derepression.  In other
words, do cells exposed to interferon make a specific messenger RNA directing
the synthesis of a protein which is the effective antiviral  agent? Dr. Friedman
has more fully discussed  the evidence  for such  a mechanism,  which was first
proposed  by Taylor  (1964)  on  the  basis  of her finding  that actinomycin  D
blocked the development of resistance  in response to interferon. The reduction
in  single-cycle  virus  yields  in  interferon  pretreated  cells  was  not  observed
when  this  pretreatment  took  place  in  the  presence  of actinomycin.  Actino-
mycin  added  after  interferon  did  not have  this  effect.  It  was  therefore  the
development  of resistance,  but not its expression,  that was sensitive  to actino-
mycin.  These  observations  established  that interferon  action  has  a require-
ment  for cellular  RNA  synthesis.  They,  however,  provided  no  information
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about  which  species  of  RNA  was  involved.  Puromycin  aminonucleoside
which  selectively  inhibits  the formation  of  ribosomal  RNA  (Farnham  and
Dubin,  1965)  had no effect on interferon action (Field et al.,  1967), suggesting
that it is the synthesis of messenger  RNA  or transfer RNA  that may  be re-
quired  for the development  of resistance.  Having demonstrated  that the de-
velopment  of resistance depends  on cellular RNA synthesis, the next step was
to try to show that there was a similar dependence on cellular protein synthe-
sis.  Experiments on the effects  of inhibitors of protein  synthesis present  some
problems  about  which I  will  speak  a little later,  and which have  made the
interpretation  of the results  of these experiments  more  difficult.  Nonetheless,
although  less clear  cut  than the  observations  on  the effects  of actinomycin,
studies  with  several  inhibitors  of  protein  synthesis  have  suggested  that  the
development  of resistance  in response to interferon may also  have a require-
ment for  host  cell protein synthesis  (Friedman and  Sonnabend,  1964,  1965;
Lockart,  1964; Levine,  1964; Dianzani et al.,  1969).
It  has been  assumed  that the fact that host cell macromolecular  synthesis
is  required  for  the  development  of resistance  means  that  there  is  a  specific
cellular  response  to  interferon.  In  other  words,  cells  exposed  to  interferon
synthesize  a specific  protein;  it has been further  assumed that this protein is
the  effective  antiviral  agent.
The evidence  needed  to show that  these hypotheses  are  correct  is, first,  a
direct  demonstration  that  interferon-treated  cells  contain  a  newly  synthe-
sized  protein  that  is  absent-or  present  in  relatively  smaller  amounts-in
untreated cells, and that this protein has antiviral activity. Despite the obvious
difficulties,  our group  at Mill Hill undertook  an  examination  of interferon-
treated  chick cells  for the presence  of a protein  or proteins which  are either
absent or present in untreated  cells in reduced amounts.
Our approach  was to incubate interferon-treated  and  untreated cells  with
the same  amino  acids but labeled  with  different  isotopes,  usually  H in the
case of the untreated cells, and  1 4C in the case  of interferon-treated  cells. The
3H-  and  4C-labeled  cells were mixed,  and various subcellular fractions  were
prepared.  The  proteins  in  the various  fractions  were  treated with  1%  SDS
and  0.5 M urea  and electrophoresed  together  on  10%  polyacrylamide  gels.
An alternative technique was to incubate the cells with amino acids-3H before
exposure  to  interferon  then  with  amino  acids-14C  during  incubation  with
interferon  or with buffer.  The experiments  were carried  out  on 2-3-day-old
monolayers  of chick  embryo  cells  using  levels  of interferon  from  30 to  100
U/107 cells,  with periods of incubation  in  the presence  of interferon of from
5 to 21  hr. The partially  purified interferon was kindly supplied by Dr. Karl
Fantes  and had a specific activity of  104-105 U/mg protein. Particular atten-
tion was  paid  to the ribosomes,  in view  of the reports  of Marcus  and  Salb
(1966)  and  of  Carter  and  Levy  (1967)  implicating  these  structures  in  the
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antiviral  action  of interferon.  Both  native  ribosomal  subunits  and  subunits
derived  by treatment  of 74S  ribosomes  with EDTA were  examined,  as well
as the  proteins that could  be removed  from the ribosomes  with 0.2  M NaCl
and 0.01  M EDTA.  In  preliminary  studies,  it had  been  found that the sedi-
mentation  in  sucrose  gradients  of ribosomes  and  their  subunits  from  inter-
feron-treated  cells did not differ  from that of ribosomes  from untreated  cells;
nor were there differences in the yield of ribosomes, the ratio of monosomes to
polysomes,  and  the  density  of the  ribosomes  in  caesium  chloride.  Cell  sap
proteins were subjected to various preliminary fractionation procedures before
electrophoretic  analysis,  and these included  precipitation  with different con-
centrations  of  ammonium  sulphate  and  fractionation  on  DEAE-cellulose
columns.
Despite many experiments under a variety of conditions we were unable to
detect a  consistent difference  in the material  derived from interferon-treated
cells.  An  example  of the  patterns  obtained  on  electrophoresis  of  proteins
derived  from the  60S ribosome  subunit is shown  in Fig.  1.
Material  derived  from  interferon-treated  cells  was  labeled  with  amino
acids  14C,  that from control cells with amino acids-3H.  The ratio of 14C to  H
radioactivity  is identical.  All the other fractions  examined gave no consistent
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FIGURE  1.  See text for explanation.
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Our negative results raise the question of whether we should in fact be able
to detect the presence of one additional  protein probably attached  to only a
proportion  of the ribosomes.  We have calculated that if one-third of the ribo-
somes in the resistant cell contain a single newly synthesized  antiviral protein
molecule,  and if the size and degree of labeling  of this protein is the same as
that of one average newly synthesized ribosomal protein, then we should have
been able to detect its presence,  even if it had  the same electrophoretic  mo-
bility  as the major  group  of ribosomal  proteins.  However,  small differences
in these assumptions would affect this conclusion  so our negative results can-
not,  therefore,  rule  out  the  possibility  that  a  newly  synthesized  protein  is
associated  with ribosomes in interferon-treated  cells.
I would  now like to return to a discussion  of some of the considerations  on
which the proposal that interferon induces the synthesis of a protein possessing
antiviral  activity  is based  and ask  two questions.  First,  how good  is  the evi-
dence that protein  synthesis  is  required  for interferon  action,  and  second,  if
this should be a reasonable  interpretation,  what evidence do we have that it
is the induced  synthesis  of a specific  protein  that is  required rather than the
continuation of normal cellular protein synthesis?
With  regard  to  the  first  question,  there  are  some  problems  inherent  in
experiments with inhibitors of protein synthesis that are difficult to overcome.
Unlike  actinomycin,  which  does  not  inhibit  the  replication  of  most  RNA
viruses, it is necessary to reverse the effects of the inhibitor of protein synthesis
when the virus  is added,  in order to determine  whether the interferon treat-
ment  has  been  effective.  Furthermore,  it  is  necessary  to  show  that  the  in-
hibitor  does not suppress RNA synthesis,  otherwise we shall  have  advanced
no further than the observations on the effects of actinomycin.  Concentrations
of  puromycin,  for  example,  have  been  used  in  some  of  these  experiments
which do inhibit RNA synthesis, and reversal of the inhibitor with respect to
the  effects  of pretreatment  on subsequent  virus  growth has not always been
complete.  This means  that the  effectiveness  of interferon  is being  compared
with a control which is itself, at least partially, inhibited. Unless these criteria,
reversibility with respect to virus growth and no inhibition of RNA synthesis,
are met, interpretation  of the inhibitor studies will be difficult. These criteria
have been met by using low doses  of puromycin,  doses which inhibited  pro-
tein synthesis  by only 50%  (Friedman  and  Sonnabend,  1965),  with fluoro-
phenylalanine  (FPA)  (Friedman  and Sonnabend,  1964;  Baron et al.,  1967),
and with  cycloheximide  (Dianzani  et  al.,  1969).  However  in  one  detailed
study, cycloheximide failed to inhibit the development of resistance  (Dianzani
et al.,  1969).  It was  suggested that the reason for this was  that the antiviral
protein  was rapidly made  when  the  inhibitor was removed,  the messenger
RNA for this protein having been synthesized while the cells were exposed to
interferon in the presence of cycloheximide.  The difficulty  with this explana-
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tion is that it implies that it is impossible to ever demonstrate the need for new
protein  synthesis  for  the development  of resistance,  using  an  inhibitor  that
readily fulfills  the criteria  mentioned;  that is,  it is  easily reversible-protein
synthesis  is  rapidly  restored  on  its  removal,  and  it  does  not  inhibit  RNA
synthesis.  The  inhibitor  will  not  affect  the  development  of  resistance  pre-
cisely because it fulfills these necessary criteria.  In the case of puromycin  and
FPA,  inhibitors  that  apparently  prevent  the  development  of resistance,  it
has required special  pleading about the instability  of the messenger  RNA  in
the presence  of these  inhibitors  to account for their effects  as  opposed to the
lack of effect of cycloheximide.
Because of the above considerations,  there is a need for some caution in the
interpretation  of the results of these experiments,  although the evidence  they
have  provided  strongly  suggests  that  the  development  of  resistance  has  a
requirement  for cellular protein synthesis.
Accepting  the  validity  of  the  inhibitor  studies,  in  that  they  show  that
interferon  action  has a requirement  for cellular  RNA  and  protein  synthesis,
I  would  like  to consider the second  question I  asked.  Does  the requirement
for RNA and protein synthesis reflect the induced synthesis of a specific protein
in response  to  interferon? The demonstration  that interferon  action depends
on RNA  and protein synthesis does not in itself permit such  a conclusion.  An
alternative explanation would be that interferon action requires the continua-
tion of normal cellular RNA and protein synthesis.  There need be no  quanti-
tative or qualitative differences  in the RNA and protein made while  cells are
exposed  to interferon.  For example,  interferon  itself may be  antiviral within
the cell, but its uptake or transport to its site of action may depend on cellular
RNA and protein synthesis.  Alternatively,  these processes  may be needed  for
the  activation  of  interferon,  or  for  its  modification.  One  argument  for  the
derepressor  model  of interferon  action  is  its  high  potency  and  that such  a
model provides an explanation of how its effects could be amplified. However,
an amplification effect could also result from mechanisms which do not require
that interferon  action  depend  on  the induced  synthesis  of a  specific  protein.
For example,  a mechanism  involving interferon  as an enzyme,  or as an agent
triggering  the  release  or activation  or modification  of a  preexisting  cellular
enzyme,  could  have this  result in that it is the  product of the  reaction cata-
lyzed  by  this  enzyme  that  is  responsible  for  the  antiviral  state.  A  specific
example  would  be a  modification  of a  newly made  tRNA.  In  this case  the
need for new RNA synthesis could be accounted for by the fact that it is only
newly synthesized tRNA that is susceptible to modification.
Thus it is possible to interpret experiments employing inhibitors to indicate
that the protein and  RNA synthesis  involved in interferon  action are neither
specifically  induced  by interferon  nor necessarily  antiviral.
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I would now like to turn to a different aspect of interferon action,  and this
concerns  the possible  role of the  ribosome  in  the expression of the  antiviral
state.
Marcus and Salb in  1966  and Carter and Levy in  1967 provided evidence
that the antiviral action  of interferon was the consequence  of a specific  ribo-
somal abnormality  induced by treatment  of cells with interferon.  Ribosomes
from interferon-treated  cells were unable to translate a viral messenger  RNA
while retaining the ability to translate cellular messenger  RNAs. The work of
Marcus  and  Salb  indicated that there were in fact two ribosomal  defects:  a
reduced  capacity to bind viral  RNA and an inability to translate  the RNA
that was bound.  In the system studied by Carter and Levy, the defect was in
the binding  of viral  RNA,  and  the inability  to translate was  regarded  as  a
consequence  of this.  Linking  their proposals  with  the derepressor  model  for
the development  of resistance, Marcus and Salb assigned  a specific role to the
new  protein  that  was  believed  to  be  made  in  response  to  interferon.  This
protein  was  termed  the  "Translational  Inhibitory  Protein"  or  TIP,  and
Marcus  and Salb  suggested that the TIP associated  with ribosomes  to cause
the functional  defects  they  described.  They provided  some  evidence  that  a
protein was involved in the abnormal ribosomal function in their demonstra-
tion  that  treatment  of the  ribosomes  with  trypsin  restored  their  apparent
capacity to translate viral  RNA  without improving  their  ability  to bind the
RNA.  That  the TIP was  a protein  newly  synthesized  on  exposure  to inter-
feron was assumed because the ribosomal abnormality was not observed when
cellular  RNA synthesis was blocked by actinomycin D during treatment with
interferon.
These  results prompted  us to  a detailed  examination,  at Mill  Hill,  of the
interaction of viral RNA and ribosomes in a cell-free amino acid incorporating
system  derived  from  CEF  (chick  embryo  fibroblasts)  and  employing  tech-
niques similar to those used by Marcus and Salb.
First,  ribosome  and cell  sap  preparations  from interferon-treated  and un-
treated cells were compared with respect to their ability to support amino acid
incorporation,  either endogenous  incorporation by a total ribosome prepara-
tion,  or  poly U-stimulated  incorporation  of  phenylalanine  by  fractionated
74S ribosomes.
A comparison  of incorporation  by systems  derived from interferon-treated
and untreated  cells is shown in Table I.
Partially purified interferon  of a specific  activity of  104-105 U/mg protein,
which was kindly supplied by Dr. Karl Fantes,  was used at concentrations  of
50 or  140  U/ml.  2-day-old  CEF  monolayers  were  used,  and  the  interferon
treatment  was  for  24  hr.  The  intrinsic  incorporation  by  a  total  ribosome
preparation  is  seen  in  this  table,  and  no  differences  were  observed  in  the
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activity of ribosome  or cell  sap preparations  derived  from interferon-treated
or untreated  cells.
Table II shows  the response  of fractionated  74S ribosomes  to poly U,  and
again  ribosomes  from  interferon-treated  and  untreated  cells  were  equally
active.
The  interaction  of these  ribosomes  with  viral  RNA  was  next  examined.
3H-labeled  Sindbis  viral  RNA  or Semliki  Forest  virus  RNA  as well  as 45S
TABLE  I
AMINO  ACID  INCORPORATION  BY  RIBOSOME-CELL  SAP
SYSTEMS  FROM  INTERFERON-TREATED  AND  CONTROL  CELLS
Incorporation  of amino acid-
1
4C  mixture
Ribosomes  Cell  sap  Exp.  I  Exp.  2  Exp.  3  Exp. 4
cpm/50 t.g ribosomes
Control  Control  5740  6100  3500  6200
Interferon*  Control  6200  5900  4750  6400
Interferont  Control  - - - 6200
Control  Interferon*  - 5950  - 6650
Control  Interferont  - - - 7300
Interferon*  Interferon*  - 6300  - 6200
Interferon  Interferont  - - - 6300
* Interferon treatments of cells were at concentrations  of from 35 to 50 U/ml.
;  Interferon treatments of cells were at a concentration of 140 U/ml.
TABLE  II
RESPONSE  TO  POLY U  OF  CELL-FREE  SYSTEMS  FROM  INTERFERON-
TREATED  AND  CONTROL  CELLS
Phenylalanine-14C  incorporation
Ribosomes  Cell sap  Poly  U  No poly  U  + Poly U
pg/0.5 mg  ribosomes  cpm/0.5 mg  ribosoms
Control  Control  12.5  1100  10,650
20  - 9900
Interferon  Control  12.5  1000  9900
20  - 9360
and  26S SFV RNA derived from infected  cells were used in different experi-
ments.  The  pattern  of  the  experiments  followed  closely  that  described  by
Marcus  and  Salb  (1966).  Radioactive  viral  RNA  was  mixed  with  frac-
tionated single ribosomes in the cold, and after holding the mixture at 0°C for
45 min in  a complete  amino  acid incorporating  system,  the fraction  of viral
RNA bound to ribosomes was analysed  by sedimentation  of the mixture in a
sucrose gradient.
The results with labeled viral RNA from different sources is shown in Table
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III. The fraction of the RNA bound  is that proportion  of the added labeled
RNA  sedimenting  at  or  more  rapidly  than  74S.  Although  there  are  some
variations  in the  absolute  amounts  of RNA  bound in different  experiments,
no differences  were noted  in the relative  amounts bound  to ribosomes  from
interferon-treated  or  untreated  cells.
The appearance in sucrose gradients of complexes formed by the viral RNA
and ribosomes is shown in Fig.  2.
Sedimentation  is from left  to right. The optical density trace  is that given
by the ribosomes.  EMC virus was  included  as a sedimentation  marker.  The
labeled RNA used in this experiment was a mixture of 45S and 26S SFV RNA
extracted from infected  cells. The RNA does form complexes,  and a substan-
TABLE  III
BINDING  OF  H-LABELED  VIRAL  RNA TO  RIBOSOMES  IN  THE
CELL-FREE  SYSTEM
RNA bound to  ribosomes
Fraction of
RNA preparation  Ribosomes  added RNA
cpm  %
SFV RNA  (26 +  45S)  Control  14,300  58
Interferon  19,070  81
SFV RNA  (45S)  Control  750  48
Interferon  562  36
Sindbis virus RNA  Control  1580  76
Interferon  1540  72
Sindbis virus RNA  Control  555  61
Interferon  694  77
Sindbis virus RNA  Control  2361  77
Interferon  2395  78
tial fraction of the RNA runs as a broad shoulder on the heavy side of the 74S
ribosome peak. On no occasion have we been  able to observe a discrete  250S
structure such as that described by Marcus and Salb and which was regarded
as a specific viral polysome that had been  formed in vitro in the cold. When
ribosomes from interferon-treated  cells were used the pattern seen on sucrose
gradient analysis was identical, and as already mentioned, the same amount of
viral RNA  associated  with  ribosomes  derived  from  interferon-treated  cells.
RNA extracted  from  purified  Sindbis  virus  or SFV  RNA  isolated  from  in-
fected cells gave similar results in experiments  of this type.
The  evidence presented  by Marcus  and  Salb,  that ribosomes  from  inter-
feron-treated cells were unable to translate viral messenger RNA's, was based
on the interpretation  that breakdown at 37C of the 250S structure formed in
the cold between ribosomes and viral RNA was the result of translation of the
viral  RNA.  The  fact that the  complexes  formed  with ribosomes from  inter-
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feron-treated  cells  did  not  break  down  on  incubation  indicated  that  such
ribosomes  were unable  to  translate  the viral  messenger  RNA.  Although  we
were  unable  to  demonstrate  a  discrete  250S  structure  in  sucrose  gradient
analyses  of the complexes  formed between  ribosomes  and  viral  RNA  in the
cold,  we did look at the  fate of the  complexes that were  formed when  these
were incubated at 37C.
Fig. 3 shows the result of such an experiment.
The ribosomes were derived from interferon-treated  cells in this experiment,
and the RNA used was 3H-labeled  SFV RNA.  Identical results were obtained
when  ribosomes  from untreated  cells were  used. The upper  curve shows  the
complexes  formed  after  a  25  min  incubation  of the  RNA and  ribosomes  at
0°C. The lower curve shows that the complexes  break down on incubation at















FIGURE  2.  Sucrose  gradient  analysis  of complexes  formed on  incubation  at 0°C in the
cell-free  system of SFV RNA  and  74S  chick  cell  ribosomes.  -,  optical density  at  260
nm;  A--A, EMC  virus titer,  (HAU);  O ...  O,  3H-labeled  SFV  RNA.
heximide,  and in a system where ATP, GTP,  and phosphoenolpyruvate  were
omitted.  It  can  be  seen that  the complexes  broke  down to  the  same extent
under  these  conditions.  That  these  treatments  were  effective  in  inhibiting
amino  acid  incorporation  is  shown  in  the  lower  diagram;  in  this  case,  en-
dogenous  incorporation  by a  total ribosome preparation  was  assayed  under
the same conditions as the incubations shown in the upper diagram.
Since  breakdown  took place under conditions where protein  synthesis was
inhibited,  it could  not be  taken  as  a  measure  of translation.  Ribonuclease
activity  could  be demonstrated  in ribosome  and  cell  sap  fractions,  and  it is
likely that this contributed to the breakdown  of the complexes we observed.
These results  are in conflict  with those of Marcus  and Salb  (1966)  and  of
Carter and  Levy  (1967)  in  that they show no differences  in the  capacity  of
ribosomes  from  interferon-treated  and  untreated  cells  to  bind  viral  RNA.
With respect to translation of the viral RNA, we have been unable to use the
index  of translation  of Marcus and  Salb, namely the  breakdown  at 37°C  of
180 SONNABEND,  KERR,  AND  MARTIN  The Antiviral State
RNA ribosome complexes  formed in the cold,  as we have found that this could
not be  correlated with amino acid incorporation.
In  vivo  studies  on  the  growth  of both  RNA  and  DNA  viruses  have  all
pointed  to viral  protein  synthesis  as  the  function  sensitive  to  inhibition  in
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FIGuRE  3.  Breakdown  of 
3H-labeled  viral  RNA  ribosome  complexes  in  the  cell-free
system,  under  conditions  inhibitory  to  amino  acid  incorporation.  A,  74S  ribosomes
from  interferon-treated  cells  mixed  with  SFV 3H-RNA  and  incubated  with  control
cell  sap in the  complete  cell-free  system for  25 min.  -- J,  at  0°C; I--,  at  37
0C;
O-  O, at 370 C in the absence of ATP, GTP,  and phosphoenolpyruvate.  B, Amino acid
incorporation  by a total ribosome preparation  derived from control cells,  assayed under
the same conditions  as those used in A.
would  seem  to be the most likely  site of interferon  action on general grounds.
Studies  in cell-free  systems  provided  an  obvious  means  of further analyzing
the mechanisms  of inhibition of viral protein synthesis.  The objectives  of these
investigations  have  been  to  study  the messenger  function  of  viral RNA  in
cell-free  systems  using  components  from  interferon-treated  cells.  However,
the significance  of the various parameters of messenger function that have been
used in these studies  is not clear. With respect to the binding of viral RNA to
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ribosomes  that  we  have  observed  and  that  was  reported  in  the  studies  of
Marcus and  Salb  (1966)  and  Carter and  Levy (1967),  there  is no indication
that this is related to the binding that occurs in the translation of a functional
messenger RNA. We believe that there must be some doubt as to the validity
of assessing  translation by breakdown on incubation  of RNA  ribosome com-
plexes formed in the cold. The inability of viral RNA to stimulate amino acid
incorporation  into  polypeptides  in  a  cell-free  system  when  ribosomes  from
interferon-treated  cells were  used has  also been reported  (Marcus  and  Salb,
1966;  Carter and Levy,  1967).  However,  unequivocal results in studies of this
type are only possible if the viral  RNA-directed incorporation  can be shown
to be meaningful,  and this entails the identification  of the product of the cell-
free incubation  as  viral specific;  in none of the studies reported has this con-
dition been met.
In view of these considerations,  we feel that there must be some doubt as to
whether  the  ribosome  is  directly  involved  at  all  in  the  antiviral  action  of
interferon.  Even  if there  should  be a ribosomal  defect in  interferon-treated
cells,  the  participation  of a  newly synthesized  TIP in the functional  abnor-
mality is highly speculative,  and as  I  have discussed  earlier, the proposal that
cells respond to interferon by making a specific protein is itself also conjectural.
One  possible  resolution  of  the  apparently  conflicting  results  in  this  field
would be if the alteration in the interferon-treated  cell were to involve a factor
or factors required  for virus protein synthesis which is not an integral part of
the ribosome,  but  which  would  be  associated  with  it under  some  isolation
procedures.  Such a factor  may  for  example be  involved  in  the initiation  of
protein synthesis, or it may be a factor concerned with a necessary processing
of the RNA before it is able to function as a messenger. Reservations regarding
the role of a newly synthesized protein would of course apply to these sugges-
tions  as  well  as to the altered  ribosome  hypothesis.
That interferon  induces  the synthesis  of a  specific  protein,  and that ribo-
somes  in  interferon-treated  cells  have  a  specific  functional  abnormality,
remain  hypotheses.  Putting  these  two  hypotheses  together  has  produced  a
third, that of the translational inhibitory protein.  Attractive as they are, they
remain  speculations,  and  I hope  they  will be returned  to their proper  place
as subjects  of controversy.
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Discussion from the Floor
Dr. Levy  (National  Institutes of Health):  In accord  with the report of Dr. Son-
nabend, we would agree  thoroughly that the demonstration  of differences  in proteins
in  interferon-treated  and  control ribosomes  is very  difficult  to  establish.  We looked
at this  perhaps  not quite as often  as you have,  but almost as often,  and  we find  no
reproducible  differences.  As a matter of fact,  the only reproducible  differences  that I
thought I hopefully  saw  were in some earlier  publications  of yours which you feel is
probably  not really meaningful.  So it may be that there aren't any.
Let's consider the question  of binding of RNA to ribosomes.  You  used the sucrose
gradient demonstration  of binding which is the same which we used. It's something of
a  nuisance  to  perform  this  kind  of  technique,  and  one  can't  handle  very  many.
Along  with  Dr. Dianzani  this  summer,  we  did  some  preliminary  work with a  dif-
ferent  technique  to  demonstrate  binding  and  possible  differences  in  binding.  We
incubated  ribosomes  with  RNA's,  and then  we  put them  through Millipore  mem-
branes.  The  single-stranded,  viral  RNA  goes through  a Millipore  membrane  quite
well,  while  that which  is  bound  to ribosomes  would presumably  be retained.  I  was
away  during  the  time Dr. Dianzani  did  the first experiments.  I spoke with him on
the telephone,  and he was very excited.  The interferon-type ribosomes bound normal
cell RNA as well  as control ones, but there was some 20-fold  difference in the ability
of  the  interferon-type  ribosomes  to bind  viral RNA.  We had  the  ribosomes  in  the
freezer  and  did  the  experiment  again  about  10  days  later.  The  differences  were
maybe  threefold.  We did the  experiment  again,  and  there  were  no differences.  I'm
not sure whether  this means the  differences were  decaying.  It could  be  that this is  a
rather  sensitive kind  of phenomenon.  I  agree  with  you,  we have  to hold  the  final
decision in abeyance.
Dr. Armstrong: I also tried these binding experiments with Millipore filters using
Sindbis virus RNA and rabbit ribosomes.  And we found exceptionally  good binding
with the whole ribosome,  with large  subunits, with small subunits,  and with  the  cell
sap  from  interferon-treated  cells  or  normal  cells-it  really  didn't  seem  to  matter,
everything bound RNA to the same  extent, sometimes  80-90 %.
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